Lupin enters into non-exclusive patent licensing agreement with Takeda

To commercialise Vonoprazan, a novel gastrointestinal drug in India

Lupin has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company (Takeda), to commercialise Vonoprazan tablets in the Indian market. The drug will be marketed under the brand name Lupin’s Lupivon and will be available in two strengths – 10 mg and 20 mg.

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India.

“We are pleased to commercialise Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address the unmet needs of our patients,” said, Rajeev Sibal, President, India Region Formulations, Lupin.